Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Lemaitre Vascular ( (LMAT) ) is now available.
On April 8, 2026, LeMaitre Vascular director Bridget Ross notified the board that she would not stand for re-election as a Class II director at the June 2, 2026 annual meeting, though she will continue to serve until her current term expires and her decision is not due to any disagreement with the company. To rebalance the staggered board structure, the board nominated current Class I director David B. Roberts to stand for election as a Class II director, and he has agreed to resign his Class I seat contingent on that election, after which the board will be reduced from eight to seven members, with two Class I, two Class II, and three Class III directors and the vacant Class I directorship eliminated.
The most recent analyst rating on (LMAT) stock is a Buy with a $117.00 price target. To see the full list of analyst forecasts on Lemaitre Vascular stock, see the LMAT Stock Forecast page.
Spark’s Take on LMAT Stock
According to Spark, TipRanks’ AI Analyst, LMAT is a Outperform.
The score is driven primarily by strong financial performance (high margins and cash generation) and constructive earnings-call guidance with shareholder-return actions. Technicals also support the rating with strong trend and momentum, though the stock appears extended. The main offset is valuation, with a high P/E and a modest dividend yield increasing the bar for continued growth execution.
To see Spark’s full report on LMAT stock, click here.
More about Lemaitre Vascular
LeMaitre Vascular, Inc. is a medical device company focused on developing, manufacturing, and marketing vascular devices and implants for the treatment of peripheral and other vascular diseases. The company serves vascular surgeons and related specialists, targeting procedures that restore blood flow in affected vessels and support long-term vascular health outcomes for patients worldwide.
Average Trading Volume: 217,490
Technical Sentiment Signal: Buy
Current Market Cap: $2.61B
For an in-depth examination of LMAT stock, go to TipRanks’ Overview page.